Edition:
India

People: Crinetics Pharmaceuticals Inc (CRNX.OQ)

CRNX.OQ on NASDAQ Stock Exchange Global Select Market

14.86USD
12:19am IST
Change (% chg)

$-1.04 (-6.54%)
Prev Close
$15.90
Open
$15.93
Day's High
$15.93
Day's Low
$14.78
Volume
13,862
Avg. Vol
71,073
52-wk High
$26.65
52-wk Low
$10.63

Struthers, R. Scott 

Dr. R. Scott Struthers Ph.D. serves as President, Chief Executive Officer, Director of the Company. Prior to Crinetics, he was senior director and head of endocrinology and metabolism at Neurocrine Biosciences, Inc., from 1998 to 2008. At Neurocrine, he initiated and led the company’s efforts to discover and develop orally active, nonpeptide GnRH antagonists, including elagolix. Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions for the life sciences and higher education markets and led contract research efforts at Biosym Technologies, from 1992 to 1995, to develop and apply computational tools for drug discovery. Dr. Struthers is also a co-founder of the San Diego Entrepreneurs Exchange, a nonprofit organization which he has served on the board of directors of since January 2009. He holds a Ph.D. in physiology and pharmacology from the University of California, San Diego based on the work he performed at the Salk Institute for Biological Studies. Dr. Struthers’ knowledge of our business, as well as his extensive development and clinical experience, contributed to our board of directors’ conclusion that he should serve as a director of our company.

Basic Compensation

Total Annual Compensation, USD 541,708
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 3,224,950
Fiscal Year Total, USD 3,766,660

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Wendall Wierenga

264,250

R. Scott Struthers

3,766,660

Marc Wilson

1,423,810

Adriana Cabre

--

Alan Krasner

1,545,780

Ajay Madan

--
As Of  31 Dec 2019